With a brutal blow from a failed RSV vaccine trial for elderly patients,last year wasn't a much one for Gaithersburg-based Novavax.
And the company's current proxy statement shows a little more approximately how the company (NASDAQ: NVAX) reacted. The company eliminated cash bonuses last year for all employees, including senior executives, and the Securities and Exchange Commission filing shows. Novavax also said senior executives would not receive annual salary increases this year and had their 2017 stock option…
Source: bizjournals.com